The 2025 IDF guidelines emphasize glycemic control remains fundamental in type 2 diabetes, while highlighting global disparities in access to newer drugs like GLP-1 agonists and SGLT2 inhibitors.
80% of T2D in LMICsIDF guidelines address global disparities in diabetes treatment access
What the researchers found
The IDF guidelines reaffirm glycemic control as the cornerstone of T2D management while recognizing SGLT2i and GLP-1 RA cardiovascular-kidney benefits, particularly emphasizing equitable access in LMICs.
Why it matters
Global diabetes guidelines must balance cutting-edge drug evidence with the reality that most patients worldwide cannot access expensive new medications, making practical glycemic control strategies essential.
How the study worked
Expert panel discussion and analysis of the 2025 IDF clinical practice guidelines based on randomized trial evidence.
What this study cannot tell us
Guidelines reflect expert consensus which may lag behind emerging evidence; implementation challenges in LMICs are acknowledged but not fully addressed.
How to read the evidence
IDF clinical practice guideline based on RCT evidence — authoritative global recommendations with strong evidence basis.
When this study was published
Published in 2026 analyzing the 2025 IDF guidelines, representing the most current global diabetes management recommendations.
The bigger picture
As GLP-1 drugs dominate headlines in wealthy countries, these guidelines remind us that effective diabetes management worldwide still depends on basic glycemic control strategies accessible to all populations.
Questions still open
- How can GLP-1 RA and SGLT2i access be expanded in low-resource settings where they could prevent the most complications?
- Will generic versions of incretin therapies close the global access gap?
Common questions
Do these guidelines recommend GLP-1 drugs for everyone with type 2 diabetes?
Why do guidelines focus on low-income countries?
Read the original research
Glycaemic control remains central in type 2 diabetes mellitus management: key learnings from the latest International Diabetes Federation guidelines.
Diabetes research and clinical practice, 234, 113173
Citation
Chan, Juliana C N; Deerochanawong, Chaicharn; Khunti, Kamlesh; Hassanein, Mohamed; Mohan, Viswanathan. (2026). Glycaemic control remains central in type 2 diabetes mellitus management: key learnings from the latest International Diabetes Federation guidelines.. Diabetes research and clinical practice, 234, 113173. https://doi.org/10.1016/j.diabres.2026.113173